European Archives - Page 28 of 982 - European Medical Journal

Fostering trust between pharma and HCPs

This infographic explores the state of trust between the healthcare and pharmaceutical industries, assessing where they stand in the rankings, how valuable pharma-HCP interactions can be and more.

Home Time Benefits in Older Leukemia Patients' Treatments

A new study analysing older adults with acute myeloid leukaemia has shed light on the significant role home time plays in treatment decision-making…

Bicaval TricValve Tricuspid Regurgitation: Late-Breaking PCR London Valves 2024

Bicaval TricValve shows safety, improves symptoms, and reduces hospitalisations in patients with severe tricuspid regurgitation.

New Model Predicts Malignancy Risk in Ovarian Masses with High Accuracy

New model has effectively predicted malignancy risk of ovarian masses, study finds.

MiCLASP Study Two-Year Outcomes: Late-Breaking PCR London Valves 2024

The MiCLASP study highlights the PASCAL system’s sustained safety and effectiveness in reducing mitral regurgitation at two years.

Combining Therapies to Treat Allergic Rhinitis in Children

A recent study explored the effectiveness of four treatment protocols, including nasal corticosteroids and antihistamines for children with allergic rhinitis.

Keep up to date with the genomic profiling in precision oncology

This series of educational webinars covers the latest developments in the precision medicine landscape in non-small cell lung cancer…

Europe's biopharma SMEs need urgent support, warns EFPIA

Europe must act urgently to back small and medium-sized enterprises (SMEs) in the biopharmaceutical sector, says the EFPIA.

SGLT-2 Inhibitors Reduce Mortality in Diabetic Kidney Transplant Recipients

SGLT-2 inhibitors significantly lower mortality and adverse events in diabetic kidney transplant recipients, study reveals.

Elias Revonta, Orcason Medical

World AMR Awareness Week with Orcason Medical’s Elias Revonta

Elias Revonta, Founder & CEO, Orcason Medical, joins the podcast to discuss why the fight against AMR needs to extend beyond awareness weeks.